ITMCTR2100004896
Recruiting
Phase 1
A randomized, double-blind, placebo-controlled trial of Qidong Bufei Decoction in treating postoperative symptoms of non-small cell lung cancer
Conditionsnon-small cell lung cancer
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- non-small cell lung cancer
- Sponsor
- Guang'anmen Hospital, China Academy of Chinese Medical Sciences.
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Postoperative patients with stage I non\-small cell lung cancer diagnosed by pathology or cytology;
- •2\. Enroll in the group within two weeks after thoracoscopy;
- •3\. Aged 18\-75 years;
- •4\. Physical condition score ECOG 0\-2 points;
- •5\. Estimated survival period \>\= 6 months;
- •6\. Neutrophils\>1\.5x10^9/L, platelets \> 100x10^9/L, hemoglobin\>9\.0g/dl; normal bilirubin or \< 1\.5xULN; AST (SGOT), ALT (SGPT)\< 2\.5xULN; serum creatinine \< 1\.5xULN.
Exclusion Criteria
- •1\. Patients who received neoadjuvant chemotherapy before surgery;
- •2\. Those who intend to receive radiotherapy, chemotherapy, targeted drug therapy and other treatment methods within 1 month after surgery;
- •3\. Patients with severe complications such as pulmonary embolism, respiratory failure, and myocardial infarction during the perioperative period;
- •4\. In other clinical trials;
- •5\. Patients during pregnancy or lactation;
- •6\. Patients with a history of mental illness that is difficult to control;
- •7\. Those who are allergic to study drugs;
- •8\. Those who cannot understand and refuse to sign the informed consent form;
- •9\. Those who cannot cooperate with the scale data collector.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Efficacy and safety study of DEB025/Alisporivir combined to Peg-IFN and Ribavirin in chronic hepatitis C genotype 1 naïve patients.Chronic Hepatitis C genotype 1 treatment-naïve patientsMedDRA version: 14.1Level: LLTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2010-022867-37-DEovartis Pharma Services AG1,040
Recruiting
Phase 2
Homoeopathic treatment of tooth problemsCTRI/2023/03/050348D N De Homoeopathic Medical College and Hospital
Not yet recruiting
Phase 2
The effect of Morus nigra extract on patients with liver cirrhosisiver cirrhosis.Fibrosis and cirrhosis of liverIRCT20140301016776N3Mashhad University of Medical Sciences80
Recruiting
Phase 4
A randomized, double-blind, placebo-controlled clinical trial of Shugan Jieyu Capsule on improving sleep disturbance in New Coronavirus pneumonia during convalescencePatients with sleep mood disorders during recovery from new coronavirus pneumoniaITMCTR2100004389Hubei Hospital of Traditional Chinese Medicine
Completed
Not Applicable
Effects of eating high-protein oral nutrition supplement (Nucare Active) improving muscle functioDiseases of the nervous systemKCT0007708DAESANG Life Science Corporation70